New drugs for type 2 diabetes mellitus: The challenge of the health care sustainability combined with a better patient care access

References

• Italian Society of Diabetology (SID). Italian standards for the care of diabetes mellitus 2023. [cited 2023 Feb]. Available from: https://www.siditalia.it/informazione-home.
   Google Scholar
• Guideline of the Italian Society of Diabetology (SID) and the Association of Medical Diabetologists (AMD). The treatment of type 2 diabetes mellitus 2023. [cited 2023 Feb]. Available from: https://snlg.iss.it/?cat=6.
   Google Scholar
• Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. Ann Intern Med. 2020;173:278–286. doi:10.7326/M20-0864.
   PubMed Web of Science ®Google Scholar
• DeMarsilis A, Reddy N, Boutari C, et al. Pharmacotherapy of type 2 diabetes: an update and future directions. Metab Clin Exp 2022;137:155332. doi:10.1016/j.metabol.2022.155332.
   PubMed Web of Science ®Google Scholar
• Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association; Council on Clinical Cardiology; and Council on Hypertension. Circulation. 2022 Mar;145(9):e722–e759. doi:10.1161/CIR.0000000000001040.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi:10.1007/s00125-022-05787-2.
   PubMed Web of Science ®Google Scholar
• The International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7:385–396.
   PubMed Web of Science ®Google Scholar
• Ahmad E, Lim S, Lamptey R, et al. Type 2 diabetes. Lancet. 2022;400(10365):1803–1820. doi:10.1016/S0140-6736(22)01655-5.
   PubMed Web of Science ®Google Scholar
• Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2022;79(18):1849–1857. doi:10.1016/j.jacc.2022.02.046.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;376:o109. doi:10.1136/bmj.o109.
   PubMedGoogle Scholar
• Zhu J, Xiaoxia Y, Zheng Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes Endocrinol. 2020;8:192–205. doi:10.1016/S2213-8587(19)30422-X.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776–785. doi:10.1016/S2213-8587(19)30249-9.
   PubMed Web of Science ®Google Scholar
• Neuen L, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–854. doi:10.1016/S2213-8587(19)30256-6.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Dagogo-Jack S, McGuire DK, et al. On the behalf of the VERTIS CV Investigators. Kidney outcomes using a sustained ≥40% decline in eGFR: a metaanalysis of SGLT2 inhibitor trials. Clin Cardiol. 2021;44:1139–1143. doi:10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi:10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stafansson BV. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446.
   PubMed Web of Science ®Google Scholar
• Taylor OM, Lam C. The effect of dipeptidyl peptidase-4 inhibitors on macrovascular and microvascular complications of diabetes mellitus: a systematic review. Curr Ther Res Clin Exp. 2020; 93:100596. doi:10.1016/j.curtheres.2020.100596.
   PubMed Web of Science ®Google Scholar
• Italian Agency of Drugs AIFA. [cited 2022 Dec]. Available from: https://www.aifa.gov.it/nota-100.
   Google Scholar
• Italian Agency of Drugs AIFA. [cited 2022 Dec]. Available from: https://www.aifa.gov.it/-/attivazione-della-prescrizione-informatizzata-dei-farmaci-in-nota-100-da-parte-dei-medici-di-medicina-generale-tramite-il-sistema-ts.
   Google Scholar
• SID AMD. Italian scientific society of diabetology. [cited 2022 Dec]. Available from: https://www.siditalia.it/.
   Google Scholar
• Ferrara F, Santilli P, Bartolini L, et al. L’importanza del magazzino logistico in periodo di pandemia: l’esperienza dell’USL Umbria 1 durante COVID-19 [The importance of the logisticwarehouse in pandemic period: the experience of the USL Umbria 1 (Perugia, Italy) during covid-19]. Recenti ProgMed. 2021 Mar;112(3):219–224. Italian. doi:10.1701/3565.35462.
   PubMedGoogle Scholar
• Ferrara F, Santilli P, Vitiello A, et al. Logistics management provides greater efficiency, governance and compliance. Int J Clin Pharm. 2021;43(5):1431–1435. doi:10.1007/s11096-021-01283-6.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Mancaniello C, Varriale A, et al. COVID-19 mRNA vaccines: a retrospective observational pharmacovigilance study. Clin Drug Investig. 2022;42(12):1065–1074. doi:10.1007/s40261-022-01216-9.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Nava L, Trama U, et al. The slow path to therapeutic adherence. Hosp Pharm. 2022;57(5):593–595. doi:10.1177/00185787221074570.
   PubMed Web of Science ®Google Scholar
• Zovi A, Musazzi UM, D’Angelo C, et al. Medicines shortages and the perception of healthcare professionals working in hospitals: an Italian case study. J. Interprofess Educat Pract. doi:10.1016/j.xjep.2021.100472
   Google Scholar
• Ferrara F, Mancaniello C, Nava L, et al. Could decreased reporting of suspected adverse reactions generate future safety concerns? Hosp Pharm. 2022;57(4):419–421. doi:10.1177/00185787211069040.
   PubMed Web of Science ®Google Scholar
• Inoue D, Nishi H, Inoue R, et al. Regional distribution of cardiologists and prescription patterns of sodium-glucose transporter-2 inhibitors in Japan. Int Heart J. 2021;62(3):592–600. doi:10.1536/ihj.20-716.
   PubMed Web of Science ®Google Scholar
• Samsky MD, Morrow DA, Proudfoot AG, et al. Cardiogenic shock after acute myocardial infarction. JAMA. 2021;326(18):1840–1850. doi:10.1001/jama.2021.18323.
   PubMed Web of Science ®Google Scholar
• Jeong S, Ji E. Global perspectives on ensuring the safety of pharmaceutical products in the distribution process. Int J Clin Pharmacol Ther. 2018;56(1):12–23. doi:10.5414/CP203151.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K. Vaccines are in short supply amid global cholera surge. Science. 2022;378(6623):938–939. doi:10.1126/science.adg0522.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Zovi A, Trama U, et al. Nirmatrelvir–remdesivir association for non-hospitalized adults with COVID-19, point of view. Inflammopharmacology. 2022;30(5):1927–1931.
   PubMed Web of Science ®Google Scholar